EuroIntervention | Editor's Choice

In this episode of Editor’s Choice, Dr Aaysha Cader and Dr Catalin Toma dive into the findings of SPIRARE II.

Dr Toma shares the strategy behind enriching the trial's design; core efficacy and safety endpoint results (RV/LV ratio & MAE rates); the mechanics and potential advantages of the Vertex technology; and future clinical horizons for mechanical thrombectomy.

Hosted on Acast. See acast.com/privacy for more information.

In this episode of Editor’s Choice, Dr Aaysha Cader and Dr Philip Urban discuss the findings of SELUTION DeNovo HBR, comparing SEB versus DES PCI strategies.

Dr Urban describes the dual-risk profile of the enrolled HBR patients and shares the hypothesis-generating results including 1-year TVF, BARC 3+ bleeding, and NACE rates which favoured the balloon arm – possibly linked to lower use of antiplatelet therapy in SEB-treated patients.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

In this episode of Editor’s Choice, Dr Aaysha Cader and Professor Gregory Lip compare the post-LAAO clinical outcomes of low-dose DOAC, DAPT, and SAPT, based on data from the TriNetX Global Network.

With limited guideline recommendations currently in place, Professor Lip summarises the findings of the comparisons; he explains why, mechanistically, reduced-dose DOAC might be preferable to antiplatelet therapy after LAAO; and shares with Dr Cader some alternative medical therapies to LAAO, which may suit certain patients better.

Hosted on Acast. See acast.com/privacy for more information.

In this episode of Editor's Choice, Dr Aaysha Cader speaks with Professor Niels van Royen and Doctor Rick Volleberg about the findings of the PECTUS-obs study.

They discuss the association between high-risk plaque and an approximately twofold increase in 5-year MACE; plaque rupture as a marker of both local and systemic vulnerability; and why combining imaging and physiology may be key to managing non-culprit lesions.

Hosted on Acast. See acast.com/privacy for more information.

In this episode of Editor's Choice, Dr Aaysha Cader speaks with Professor Huimin Chu about LAAC with AnchorMan versus Watchman 2.5 devices.

They discuss how the 12-month results of the SAFE-PROTECT trial indicated the non-inferiority of the novel AnchorMan occluder for both primary and secondary endpoints: clinical success and LAA closure success at 1 year. This study found that the AnchorMan’s design, intended to improve sealing, resulted in significantly lower peridevice leak ≥3 mm compared to Watchman 2.5.

Hosted on Acast. See acast.com/privacy for more information.

In this episode of Editor's Choice, Doctor Aaysha Cader speaks with Doctor Shin Nagai and Professor Toyoaki Murohara about the connection between door-to-unload time and mortality in STEMI-CS patients.

They discuss how the J-PVAD registry data confirm that early unloading and prompt revascularisation are paramount; as high-volume centres achieve these targets more consistently, organised shock systems of care, such as hub-and-spoke models, appear invaluable.

Hosted on Acast. See acast.com/privacy for more information.

In this episode of Editor's Choice, Doctor Aaysha Cader speaks with Professor Giuseppe Tarantini about the current state-of-the-art on TAVI and coronary interventions, recently published in EuroIntervention.

Professor Tarantini shares insights on managing the complex interaction between CAD, PCI, and TAVI; the value of CT imaging and angiography in strategy planning; and how to optimise outcomes in different clinical scenarios.

Hosted on Acast. See acast.com/privacy for more information.

In this episode of Editor’s Choice, Dr Aaysha Cader speaks with Dr Juan Miguel Ruiz-Nodar about the results of the GLUCO-TAVI trial, recently published in EuroIntervention.

They discuss the impact of glucocorticoid therapy on reducing permanent pacemaker implantation (PPI) following TAVI, highlighting a 50% relative risk reduction at one month. Dr Ruiz-Nodar also shares insights into the mechanisms behind these findings and outlines plans for a larger randomised trial to confirm the results and define optimal dosing and treatment duration.

Hosted on Acast. See acast.com/privacy for more information.

In this episode of Editor’s Choice, Dr Aaysha Cader speaks with Doctor Birgitte Andersen about the latest findings from the FAVOR III Europe trial, recently published in EuroIntervention.

They discuss the 2-year follow-up comparing quantitative flow ratio (QFR) and fractional flow reserve (FFR), including the key outcome that QFR did not demonstrate non-inferiority at one year. Dr Andersen explores potential explanations, including concerns around reproducibility and early event rate differences, and highlights the need for further research to identify patient populations best suited for angiography-based physiological assessment.

Hosted on Acast. See acast.com/privacy for more information.